The study of Zablocka et al. compared the value of assessing TILs in I and II stages of nodular melanoma (n = 56) and superficial spreading melanoma (n = 29), along with BRAF mutational status and their associations with clinicopathological characteristics. This evidence concerns the gene BRAF and superficial spreading melanoma.